References
Filters: Akiyama-2019b is [Clear All Filters]
Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016.
. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-1135.
. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-583.
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830-836.
Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540. doi:10.2807/1560-7917.ES.2017.22.21.30540.
. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61(5):pii: e02558-16. doi:10.1128/AAC.02558-16. Print 2017 May.
. Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes. J Hepatol. 2017;66(1):S324.
. Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C infection. J Pediatr. 2019;(207):90-96. doi:10.1016/j.jpeds.2018.12.012.
. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49(1):99-106. doi:10.1111/apt.15043.
. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naïve or experienced patients. Am J Gastroenterol. 2017;112(12):1824-1831. doi:10.1038/ajg.2017.399.
. Prognostic molecular markers in pediatric liver disease - Are there any?. Biochim Biophys Acta Mol Basis Dis. 2019;(1865):577-586.
. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res. 1996;20(1 Suppl):95A-100A.
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053-2059.
. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196-201.
. . Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis. 2014;1(3):ofu110.
. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100-105.
. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017;30(2):196 - 208.
. Interactions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir [poster #453]. Conference on Retroviruses and Opportunistic Infections. 2016.
. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002;97(9):2408-2414.
.